Incidence, clinical features and outcome of essential thrombocythaemia in a well defined geographical area

European Journal of Haematology

Volumn 65, Issue 2, 2000, Pages 132-139

  Jensen, Morten Krogh ^a,b   De Nully Brown, Peter ^b   Nielsen, Ove Juul ^b   Hasselbalch, Hans Carl ^b  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b Rigshospitalet   (Denmark)

Author keywords

Acetylsalicylic acid; Epidemiology; Essential thrombocythaemia; Outcome; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID;

ADULT; AGED; ARTICLE; DENMARK; FEMALE; GEOGRAPHIC DISTRIBUTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; DENMARK; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; SEX FACTORS; SURVIVAL ANALYSIS; THROMBOCYTHEMIA, HEMORRHAGIC; TREATMENT OUTCOME;

EID: 0033859892     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0609.2000.90236.x     Document Type: Article

References (28)

1. Life expectancy of patients with chronic nonleukemic myeloproliferative disorders
2. Major vascular complications in essential thrombocythemia: A study of the predictive factors in a series of 148 patients
3. Prevention and treatment of thrombotic complications in essential thrombocythaemia: Efficacy and safety of aspirin
4. Hamorrhagische thrombocythamie bei vascularer schrumpfmilz
5. Primary or hemorrhagic thrombocythemia
6. Hemorrhagic thrombocythemia: A critical review
7. Essential thrombocythemia. Clinical characteristics and course of 61 cases
8. 9/1 be used as a diagnostic criterion in essential thrombocythaemia? An analysis of the natural course including early stages
9. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia
10. Thrombotic and hemorrhagic complications in essential thrombocythemia. A retrospective study of 103 patients
11. No treatment for low-risk thrombocythaemia: Results from a prospective study
12. Essential thrombocythemias. Clinical evolutionary and biological data
13. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis
14. Historical perspective on the treatment of essential thrombocythemia and polycythemia vera
15. Essential thrombocythemia in young adults
16. The management of thrombocytosis
17. Aspirin in essential thrombocythemia: Status quo and quo vadis
18. Clinical parameters for determining when and when not to treat essential thrombocythemia
19. Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: An Olmsted County study
20. Summerising indices for comparison of cancer incidence data
21. Non-parametric estimation from incomplete observation
22. Age and sex distributions of hematological malignancies in the UK
23. Clinical course of essential thrombocythemia in 147 cases
24. Controlled and uncontrolled thrombocytosis. Its clinical role in essential thrombocythemia
25. Cost-effectiveness model of a phase II clinical trial of a new pharmaceutical for essential thrombocythemia: Is it helpful to policy makers?
26. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: High proportion of cases with 17p deletion
27. Therapeutic dilemmas: Balancing the risk of bleeding, thrombosis, and leukemic transformation in myeloproliferative disorders
28. New drugs in essential thrombocythemia and polycythemia vera